Colony Group’s scPharmaceuticals SCPH Stock Holding History

Colony Group’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-23,209	Closed	-$131K	–	523
2018 Q2	$131K	Buy	+23,209	New	+$238K	0.01%	486

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Colony Group's SCPH Position: Q3 2018 in Review

Colony Group sold out of scPharmaceuticals (SCPH) in Q3 2018, closing a stake of 23,209 shares — an estimated $131K sold.

Colony Group first reported a position in SCPH in Q2 2018 and held it in 1 quarter. The position peaked at $131K in Q2 2018. 35 funds tracked by Wall St. Rank hold SCPH as of Q3 2018.

Colony Group reported no remaining scPharmaceuticals position as of Q3 2018 after selling out during the quarter.
Colony Group sold 23,209 scPharmaceuticals shares in Q3 2018, an estimated $131K.
Colony Group first reported a position in scPharmaceuticals in Q2 2018 and held it in 1 quarter.
Colony Group's scPharmaceuticals position peaked at $131K in Q2 2018.
35 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2018.

Based on Colony Group's 13F filing for Q3 2018, filed 14 Nov 2018.